The Promise of mRNA Vaccines: A Biotech and Industrial Perspective


Authors: N.A.C Jackson, K.E. Kester, D. Casimiro, S. Gurunathan and F. DeRosa

Journal: npj Vaccines

DOI: 10.1038/s41541-020-0159-8

Publication - Abstract

February 04, 2020

Vaccines Nucleic Acid Lipid Nanoparticles mRNA

Abstract

mRNA technologies have the potential to transform areas of medicine, including the prophylaxis of infectious diseases. The advantages for vaccines range from the acceleration of immunogen discovery to rapid response and multiple disease target manufacturing. A greater understanding of quality attributes that dictate translation efficiency, as well as a comprehensive appreciation of the importance of mRNA delivery, are influencing a new era of investment in development activities. The application of translational sciences and growing early-phase clinical experience continue to inform candidate vaccine selection. Here we review the state of the art for the prevention of infectious diseases by using mRNA and pertinent topics to the biotechnology and pharmaceutical industries.

limit search to this category
Advanced Search

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Abstract

Sep 29, 2020
Nature Communications

Development of an ObLiGaRe Doxycycline Inducible Cas9 System for Pre-clinical Cancer Drug Discovery

A. Lundin, M.J. Porritt, H. Jaiswal, F. Seeliger, C. Johansson, M. Maresca et. al.

mRNA Oncology Nucleic Acid Lipid Nanoparticles
Read More


Publication - Abstract

May 26, 2016
Journal of Control Release

Influence of Particle Size on the in Vivo Potency of Lipid Nanoparticle Formulations of siRNA

S. Chen, Y.Y. Tam, P.J. Lin, M.M. Sung, Y.K. Tam and P.R. Cullis

siRNA Nucleic Acid Lipid Nanoparticles Genetic Medicine

Lipid nanoparticles (LNP) can provide a clinically effective method for delivering small interfering RNA (siRNA) to silence pathological genes in hepatocytes. The gene silencing potency of these LNP-siRNA systems has been shown ...

Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Cytiva, formerly Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
Sign Up